ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) today announced that Henriette Mersebach will step down as Executive Vice President, Research and Development, and as a member of the Board of Management, ...

To schedule a 1x1 meeting with the Company, please contact your Leerink Partners institutional sales representative.

Bluejay Diagnostics (NASDAQ: BJDX) today announced that as of February 19, 2026, all of the prefunded warrants issued by the Company in its October 2025 private placement have been fully exercised, ...

Following the launch of SYNICEM™ antibiotic loaded preformed spacers in the UK last year, Biocomposites was already planning to follow this up with the launch of their SYNICEM™ bone cements. This UK ...

YWECARE, an Australia-wide NDIS service provider founded by 25-year-old entrepreneur Mahmoud Khatib, is now supporting more than 100 participants across Sydney, Melbourne, and surrounding regions — ...

Summit Pharmaceuticals International Corp. to serve as exclusive distributor for cell culture supplements in Japanese Market. The agreement marks PL BioScience’s first exclusive distribution ...

The clinically meaningful benefit seen with giredestrant could enable an important new treatment option to help delay disease progression or death in people with advanced, ER-positive breast cancer,” ...

ALK expects to continue its trajectory of double-digit revenue growth and higher earnings in 2026. The EBIT margin is planned to remain in line with ALK’s long-term earnings ambitions reflecting that ...

Poster number: P0932 Title: The First-in-Class SIK3 Inhibitor O3R-5671 Demonstrates Optimal Pharmacokinetics and Potent and Sustained Pharmacodynamic Activity in Human Participants Presentation time: ...

Ramsay Générale de Santé (“ Ramsay Santé ” or the “ Group ”) takes note of the proposal announced today (the “ Proposal ”) by Ramsay Health Care Limited (“ RHC ”) to distribute its 52.79% shareholding ...

Adjusted EBITDA loss for the TMS segment of US$21.7 million, expenditure consistent with first half, demonstrating inter-company cost control (H1 2025: Adjusted EBITDA loss of US$12.7 million). Telix ...

DALLAS, Feb. 19, 2026 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc. (NYSE: AMN), the leader and innovator in total talent solutions for healthcare organizations across the United States, today ...